Trial Name | Principal Investigator | Intervention | Population |
---|
Antioxidants |
Alzheimer's Disease in Down Syndrome: Antioxidant Trial | Ira Lott | Vitamins E and C, alpha-lipoic acid | People ages 40+ with Down syndrome and AD |
Antioxidant Trial** | Douglas Galasko | Vitamins E and C, alpha lipoic acid, coenzyme Q | People with AD |
GEM (Ginkgo Evaluation of Memory)† | Steven DeKosky | Ginkgo biloba | People ages 75+ |
PREADVISE (Prevention of Alzheimer's Disease by Vitamin E and Selenium)‡ | William Markesbery | Vitamin E, selenium, Vitamin E + selenium | Men ages 60-90 participating in SELECT |
Vitamin E in Aging Persons with Down Syndrome | Arthur Dalton | Vitamin E | People ages 50+ with Down syndrome, at high risk of developing AD |
|
Cardiovascular |
ACCORD-MIND (Action to Control Cardiovascular Risk in Diabetes—Memory in Diabetes)‡ | Lenore Launer | Intensive glucose, blood pressure, and lipid management | People ages 40-79 with type 2 diabetes |
CLASP (Cholesterol Lowering Agent to Slow Progression of Alzheimer's Disease Study)** | Mary Sano | Simvastatin | People with AD |
ESPRIT (Evaluating Simvastatin's Potential Role in Therapy) | Cynthia Carlsson | Simvastatin | People ages 35-69 at high risk of AD (family history) |
|
Omega-3 Fatty Acids |
AREDS2 (Age-Related Eye Disease Study 2)† | Emily Chew and John Paul SanGiovanni | Macular xanthophylls (lutein and zeaxanthin) and/or omega-3 fatty acids (DHA and EPA) | People ages 50-85 with age-related macular degeneration (AMD) |
DHA (Docosahexaenoic Acid), an Omega-3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease** | Joseph Quinn | DHA | People with AD |
|
Passive Immunization |
Immune Globulin Intravenous (IGIV) for Treatment of Alzheimer's Disease** | Norman Relkin | IGIV | People with AD |
|
Hormones |
Alzheimer's Disease: Potential Benefit of Isoflavones | Carey Gleason | Novasoy (soy isoflavones–phytoestrogens) | People with AD |
ELITE (Early Versus Late Intervention with Estradiol) | Howard Hodis | 17 β-estradiol | Healthy early (less than 6 years) and late (10 years+) menopausal women |
KEEPS-CA (Kronos Early Estrogen Prevention Study—Cognitive and Affective Study)‡ | Sanjay Asthana | Oral conjugated equine estrogen (CEE, or Premarin®) and transdermal 17 β-estradiol | Healthy perimenopausal women, ages 42-58 |
Raloxifene for Women with Alzheimer's Disease | Victor Henderson | Raloxifene (selective estrogen receptor modulator, or SERM) | Older women with AD |
SMART (Somatotrophics, Memory, and Aging Research Trial) | Michael Vitiello | Growth hormone releasing hormone (GHRH) | People with aMCI and healthy people, ages 55-80 |
Testosterone Supplementation in Men with MCI | Monique Cherrier | Testosterone | Older men with aMCI and low testosterone |
|
Diabetes |
Glucose Regulation and Memory in Alzheimer's Disease | Suzanne Craft | Diet, triglyceride emulsion, rosiglitazone | People with AD (all studies), age-matched healthy older adults (diet) |
Metformin in Amnestic MCI | Jose Luchsinger | Metformin | Overweight people with aMCI |
RECALL (Rosiglitazone Effects on Cognition for Adults in Later Life) | Suzanne Craft | Rosiglitazone | People with aMCI |
SNIFF 120 (Study of Insulin to Fight Forgetfulness, 120 Days) | Suzanne Craft | Intranasal insulin | People with aMCI and AD |
|
Diabetes and Exercise |
POEM (Pioglitazone or Exercise to Treat Mild Cognitive Impairment) | Robert Schwartz | Pioglitazone, endurance exercise training | Older people with aMCI and metabolic syndrome |
|
Exercise |
Exercise and Cognitive Aging | Robert Krikorian | Aerobic exercise | People with aMCI |
Exercise and Health Promotion for MCI: A Controlled Trial | Linda Teri | Two exercise programs | People with aMCI and cognitively intact older people |
|
Exercise and Cognitive Training |
SHARP-P (Seniors Health and Activity Research Program Pilot) | Mark Espeland | Physical activity, cognitive training | People at risk of aMCI, ages 70-85 |
|
Other Trials |
Antipsychotic Discontinuation in Alzheimer's Disease | Dev Devanand | Risperidone | People with AD |
CITAD (Citalopram for Agitation in AD) | Constantine Lyketsos | Citalopram | People with AD |
Huperzine A in Alzheimer's Disease | Paul Aisen | Huperzine A | People with AD |
Phase II Trial of AAV-NGF Gene Delivery in Alzheimer's Disease | Paul Aisen | Nerve growth factor (NGF) gene | People with AD |
Pilot Phase II Study to Evaluate the Impact of Biomarkers of Resveratrol Treatment** | R. Scott Turner | Resveratrol | People with AD |
Transdermal Nicotine Treatment of MCI | Paul Newhouse | Nicotine patch | People with aMCI |
TREA (Treatment Routes for Exploring Agitation) | Jiska Cohen-Mansfield | TREA, a systematic approach to individualizing nonpharmacological interventions for people with dementia | Nursing home residents with AD/dementia |
Trial to Assess Biomarker Outcomes, Safety, and Tolerability of Lithium Carbonate** | Pierre Tariot | Lithium | People with AD |
VALID (Valproate in Dementia)** | Pierre Tariot | Valproate | People with AD |